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Background: Seasonal affective disorder (SAD) is a subtype of recurrent depression involving major depressive
episodes during the fall and/or winter months that remit in the spring. The central public health challenge in the
management of SAD is prevention of winter depression recurrence. Light therapy (LT) is the established and best
available acute SAD treatment. However, long-term compliance with daily LT from first symptom through
spontaneous springtime remission every fall/winter season is poor. Time-limited alternative treatments with effects
that endure beyond the cessation of acute treatment are needed to prevent the annual recurrence of SAD.
Methods/design: This is an NIMH-funded R01-level randomized clinical trial to test the efficacy of a novel, SAD-tailored
cognitive-behavioral group therapy (CBT) against LT in a head-to-head comparison on next winter outcomes. This project
is designed to test for a clinically meaningful difference between CBT and LT on depression recurrence in the next winter
(the primary outcome). This is a concurrent two-arm study that will randomize 160 currently symptomatic community
adults with major depression, recurrent with seasonal pattern, to CBT or LT. After 6 weeks of treatment in the initial
winter, participants are followed in the subsequent summer, the next winter, and two winters later. Key methodological
issues surround timing study procedures for a predictably recurrent and time-limited disorder with a focus on long-term
outcomes.
Discussion: The chosen design answers the primary question of whether prior exposure to CBT is associated with a
substantially lower likelihood of depression recurrence the next winter than LT. This design does not test the relative
contributions of the cognitive-behavioral treatment components vs. nonspecific factors to CBT’s outcomes and is not
adequately powered to test for differences or equivalence between cells at treatment endpoint. Alternative designs
addressing these limitations would have required more patients, increased costs, and reduced power to detect a
difference in the primary outcome.
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Winter seasonal affective disorder (SAD) is a subtype of
recurrent depression involving major depressive episodes
during the fall and/or winter months that remit in the
spring [1]. SAD prevalence increases with latitude in the
US, ranging from 1.4% in Florida to 9.9% in Alaska [2,3].
Averaging across latitude, SAD affects an estimated 5% of
the US population [4]—over 14.5 million Americans. Un-
treated SAD-related major depressive episodes last, on
average, about 5 months of the year before spontaneous
springtime remission (personal communication, Norman
E. Rosenthal, MD, May 2005) and are associated with sig-
nificant impairments in overall health, emotional well-
being, and daily and social activities [5]. In a multi-site
study including over a thousand SAD patients, partici-
pants reported a mean age for onset of 27.2 years and, on
average, 13.4 past fall/winter major depressive episodes
[6]. Taken cumulatively, these data suggest that SAD pa-
tients spend over 40% of the year struggling with substan-
tial depressive symptoms during most years, beginning in
young adulthood.
As a first-line SAD treatment, clinical practice guide-
lines recommend daily light therapy (LT) from onset of
first symptom through spontaneous springtime remis-
sion each fall/winter season [7]. LT is the established
and best available acute SAD treatment. A recent quan-
titative analysis of trials comparing LT to credible con-
trols concluded that LT is associated with significant
reductions in depression severity for SAD in the initial
winter [8]. A pooled analysis of LT studies [9] concluded
that 53% of individuals with SAD overall and 43% of
moderate to severe SAD cases meet remission criteria by
the end of an LT trial.
LT, like most psychiatric treatments, is a palliative treat-
ment that needs to be continued with regularity over time
to prevent relapse and recurrence; however, available data
suggest that the majority of SAD patients are not willing/
able to comply with the treatment over subsequent fall/
winter seasons. A retrospective follow-up survey of SAD
patients treated with LT at the NIMH between 1981 and
1985 (mean follow-up interval = 8.8 years) revealed that
only 41% of patients continued regular use of LT [10].
When queried as to why they discontinued using LT, per-
ceived “ineffectiveness” and “inconvenience” were the two
most commonly cited reasons. In the only clinical trial to
include a planned, prospective follow-up of treated SAD
participants during the next fall/winter season [11], only 4
out of 36 patients (11%) who received LT in the trial
reported any use of LT during the next winter, and only 2
of those 4 reported using LT at a frequency, duration, and
treatment length that would be expected to confer thera-
peutic benefits [7].
Therefore, as many as 47% of individuals with SAD do
not remit with LT in the initial winter [9], and aminority of those treated acutely with LT continue using
it over subsequent winters [10,11]. Extrapolating these
data to the US prevalence of the disorder, over 11 million
Americans could potentially benefit from the development
of supplementary or alternative treatments, including 6.8
million that are projected to be non-responders to LT plus
another 4.5 million that are projected to be LT responders,
but will stop using the treatment. Ideal alternative treat-
ments would be time-limited (i.e., acute treatment com-
pleted in a discrete period vs. daily treatment every fall/
winter indefinitely), easier to implement in the long run
relative to 5 months of daily LT each year, and have more
durable effects than LT (i.e., effects that endure beyond
the cessation of acute treatment to prevent annual depres-
sion recurrence).
Cognitive therapy for depression [12] is a time-limited
psychotherapy treatment that appears to confer benefits
that extend beyond the point of treatment termination
[13,14]. Several studies have found that depressed patients
who demonstrated a clinical response to cognitive therapy
had a reduced risk of depression relapse as compared to pa-
tients who initially responded to antidepressant medica-
tions [15-18]. In addition to reducing the more proximal
risk of relapse, one trial found that patients who had recov-
ered from the treated episode with cognitive therapy dem-
onstrated a reduced risk for a wholly new depressive
episode onset (i.e., recurrence) relative to patients who had
recovered from the initial episode with pharmacotherapy
[16]. If these long-term outcomes for cognitive therapy
generalize to SAD, the treatment could represent a more ef-
fective, practical, and palatable approach to long-term SAD
management than LT. The integrative, cognitive-behavioral
model of SAD [19] proposes a psychological vulnerability
in SAD onset and maintenance, involving negative thinking
biases, rumination, and disengagement from potentially en-
joyable activities, which can be targeted by a SAD-tailored
cognitive-behavioral therapy (CBT).
The primary aim of this NIMH-funded R01-level ran-
domized clinical trial is to test the efficacy of CBT against
LT in a larger, more definitive randomized head-to-head
comparison on next winter outcomes in an intent-to-treat
(ITT) analysis using all randomized participants. This pro-
ject is focused on long-term depression outcomes in SAD.
The primary aim tests for a clinically meaningful diffe-
rence between CBT and LT on depression recurrence in
the next winter (the primary outcome). A second annual
winter follow-up will obtain preliminary data on the com-
parative effects of CBT vs. LT two winters after the initial
winter of study treatment. In characterizing the course of
major depressive disorder, the term “recurrence” refers to
the onset of a wholly new major depressive episode occur-
ring after recovery (i.e., full remission with minimal symp-
toms) from a previous episode [20]. The central public
health challenge in the management of SAD is prevention
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tice will be impacted if prior CBT is associated with fewer
SAD recurrences than initial treatment with LT.
Pilot and feasibility studies
Prior to the commencement of this randomized clinical
trial (RCT), Rohan and colleagues developed a novel, SAD-
tailored, group CBT intervention and pilot tested it in an
initial feasibility trial [21] and a controlled RCT [22]. This
group subsequently published a follow-up report on next
winter outcomes from the patients in these studies [11].
These studies were conducted with community adults in
the greater Washington, D.C., area at the Uniformed Ser-
vices University of Health Sciences in Bethesda, MD. In the
feasibility study [21], 26 adults with SAD were randomly
assigned to one of three 6-week treatments: CBT, light
therapy (LT), or the combination of CBT and LT together
(CBT+LT). Participants, in general, improved over all three
treatments with large pre- to post-treatment changes in de-
pression severity on blind interviewer- and patient-rated
measures. The trial showed promise for the utility of CBT
in acute SAD treatment, but was limited by the small sam-
ple size and lack of a control group. Therefore, the next
study was a pilot controlled RCT [22] to better rule-out al-
ternate explanations for treatment effects such as the pas-
sage of time or regression to the mean. The study
maintained the three active treatment cells, but added a
concurrent wait-list control group (WLC; 6 weeks of
weekly symptom monitoring followed by treatment with
LT) to the design. In the ITT sample of 61 randomized par-
ticipants, all three active treatments (1) had significantly
lower depression severity at post-treatment than WLC
across continuous outcomes and (2) significantly improved
over the 6 weeks, whereas WLC did not. Only CBT+LT
(73%) had a significantly higher proportion of remissions
than WLC (20%) at treatment endpoint.
Participants who were randomized to CBT, LT, or
CBT+LT and who had not dropped out of the study by
the end of acute treatment phase were invited to return
to the laboratory for a naturalistic follow-up visit during
the subsequent winter season (i.e., in January or February
when SAD symptoms are typically at their worst). The
follow-up report [11] was an ITT analysis of all random-
ized participants based on multiple imputation to esti-
mate next winter outcomes for the 17 randomized
individuals who dropped out during treatment, were
withdrawn from protocol, or were lost to follow-up. The
CBT (7.0%) and CBT+LT (5.5%) groups had significantly
smaller proportions of winter depression recurrences
than the LT group (36.7%). Solo CBT, but not combi-
nation treatment, was also associated with significantly
lower interviewer- and patient-rated depression severity
the next winter as compared to solo LT. Among com-
pleters who provided follow-up data, all statisticallysignificant differences between the solo CBT and LT groups
persisted after adjustment for ongoing treatment with LT,
antidepressants, and psychotherapy. In contrast, CBT+LT
and LT groups did not differ on next winter outcomes after
adjustment for ongoing treatments. Therefore, despite ha-
ving the highest post-treatment remission rate, initial treat-
ment with combined CBT+LT did not appear to show the
same lasting benefit over solo LT treatment on next winter
outcomes as initial treatment with solo CBT. Observed
differences between solo CBT and solo LT the next winter
(i.e., a 30% difference in depression recurrence and 6- to 7-
point differences in continuous depression scores) were
large, clinically meaningful, and apparently not secondary
to ongoing treatment use. Therefore, these findings require
replication in a larger, more definitive study to determine
whether CBT represents a more effective, practical ap-
proach to long-term SAD management than LT.
Study aims
The primary aim is to compare the efficacy of CBTand LT
on depression recurrence status, symptom severity, and
remission status during the next winter season (i.e., the
next wholly new winter season after the initial winter of
treatment), which we argue to be the most important time
point for evaluating clinical outcomes following SAD
intervention. The hypothesis is that CBT will be associated
with a smaller proportion of depression recurrences, less
severe symptoms, and a higher proportion of remissions
than LT in the next winter. The second aim is to compare
the efficacy of CBT and LT on symptom severity and re-
mission status at post-treatment (treatment endpoint). It
is hypothesized that CBT and LT will not differ on post-
treatment outcomes. An exploratory aim is to compare
CBT and LT on recurrence, symptom severity, and remis-
sion two winters after treatment completion.
Methods/design
Design overview
This research was approved (IRB #08-116) by the Com-
mittee on Human Research in the Behavioral Sciences in
the Research Protections Office at the University of
Vermont, the site where the work is being conducted. This
is a concurrent two-arm study that randomizes individuals
experiencing a current SAD-related depressive episode to
6 weeks of treatment with group cognitive-behavioral
therapy (CBT) or light therapy (LT). The primary end-
point is depression recurrence in the next winter, testing
for two-sided differences in depression recurrence in one
treatment condition relative to the other in an intention-
to-treat (ITT) analysis. The proposed trial goes beyond
prior studies in four ways. (1) This study augments the
generalizability of prior data by relaxing the inclusion/ex-
clusion criteria to allow for comorbid diagnoses and stable
antidepressant medication use and by demonstrating the
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facilitate the CBT groups. (2) Recurrences and potential
intervening variables that could affect outcome (e.g., new
treatments, summer remission status) are prospectively
tracked in the interim between treatment endpoint and the
following winter. (3) This study includes a second annual
winter follow-up to obtain preliminary data on the com-
parative effects of CBT vs. LT two winters after the initial
winter of study treatment. (4) The influence of potential
modifiers on the effects of CBT vs. LT will be examined, in-
cluding demographic variables, baseline depression severity,
comorbidity, baseline antidepressant medication status, and
complete or incomplete summer remission status.
Sample size and statistical power
This RCT is designed to definitively test for a significant
and clinically meaningful difference between CBT and LT
on depressive episode recurrence during the next winter
season (the primary endpoint). The true difference be-
tween CBT and LT (and the difference we observe in this
more rigorous design) may be smaller than what was ob-
served in the above pilot study. To determine sample size,
the more conservative estimate of a 23% difference in re-
currence was used, based on a worst case scenario as-
sumption that all subjects who dropped out of the pilot
studies at any time from randomization through the next
winter follow-up would have evidenced a recurrence the
next winter (52% in LT vs. 29% in CBT in the ITT sample).
If the true difference is 23%, 80 participants per group
(total N = 160) are required to provide 80% power to de-
tect a significant difference in recurrence between CBT
and LT with a 2-sided test and alpha = 0.05. With 80 par-
ticipants per group, there is also 80% power to detect a
5-point difference in next winter continuous depression
scores based on variance estimates from a worst-case sce-
nario analysis of pilot data whereby pre-treatment scores
were substituted for any missing next winter scores (14.3 ±
11.5 for CBT vs. 19.5 ± 11.5 for LT on the Structured Inter-
view Guide for the Hamilton Rating Scale for Depres-
sion—Seasonal Affective Disorder Version).
Participants: inclusion and exclusion criteria
Adult community volunteers, aged 18 or older, are
recruited for this study via local newspaper and radio ad-
vertisements and referrals from local health clinics begin-
ning in September of each year. Inclusion criteria are: (a)
DSM-IV-TR criteria for major depression, recurrent, with
seasonal pattern, (b) Structured Interview Guide for the
Hamilton Rating Scale for Depression—Seasonal Affective
Disorder Version (SIGH-SAD) criteria for a current SAD
episode (see below), and (c) no usage or stable use of anti-
depressants (i.e., a consistent dose of the same medication
maintained for at least the past 4 weeks with no plans to
change the medication or dose). Exclusion criteria include:(a) current LT or psychotherapy for depression or plans to
initiate such treatment during the winter of study, (b) past
LT or CBT for SAD, (c) presence of a comorbid axis I dis-
order that requires immediate treatment, (d) acute and
serious suicidal intent, (e) positive laboratory findings for
hypothyroidism at medical workup, and (f) plans for ex-
tended (>1 week) vacations or absences from the area
through the coming March. Regarding the comorbidity
exclusion (c), decisions are made on a case-by-case basis,
but psychotic disorders, substance abuse/dependence, and
bipolar-type SAD are uniformly excluded. Our criteria
strike a balance between internal and external validity in
ensuring that eligible volunteers receive a different experi-
ence in our CBT or LT conditions vs. a repetition of a past
treatment while including a sample that generalizes to
real-world SAD patients in terms of comorbidity and
pharmacotherapy.
Screening and enrollment
Given SAD’s inherent seasonal pattern, recruitment for
this study begins each September and continues through
mid-January. Individuals who respond to advertisements
undergo a brief phone screening to assess inclusion/exclu-
sion criteria. Respondents who do not endorse DSM-IV
criteria for major depression, recurrent, with seasonal pat-
tern and/or who satisfy any exclusion criterion on the
phone screen receive a referral list. Respondents who ap-
pear to meet criteria on the phone screen are invited to re-
view the informed consent document. We obtain
informed consent before proceeding with any further
study procedures. If they consent, the full Structured Cli-
nical Interview for DSM-IV Axis I Disorders—Clinician
Version (SCID-CV) is administered at an in-person
screening visit. If a diagnosis of major depressive disorder,
recurrent, with seasonal pattern is confirmed on the SCID
and no axis I disorder requiring more immediate treat-
ment is revealed, the Structured Interview Guide for the
Hamilton Rating Scale for Depression—Seasonal Affective
Disorder Version (SIGH-SAD) is administered to assess
SIGH-SAD criteria for a current SAD episode. If SIGH-
SAD criteria are not met, the individual is invited to
attend SIGH-SAD interviews every other week. When
a potential participant meets SIGH-SAD criteria for a
current SAD episode, he or she is asked to attend a medical
workup involving a routine physical examination and
medical history to characterize the sample and assess the
hypothyroidism exclusion. These evaluations are per-
formed at the University of Vermont Clinical Research
Center in the College of Medicine by a Physician’s Assist-
ant. A nurse performs venipuncture to measure levels of
TSH and thyroxine to screen for hypothyroidism. Individ-
uals with laboratory results suggestive of hypothyroidism
are excluded and referred for treatment. If the medical
workup suggests normal thyroid functioning, the participant
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conclusion of which he or she is randomized to a treatment
group and enrolled in the study. At the end of January,
SIGH-SADs are discontinued for any potential participant
who did not meet the threshold for a SAD episode because
of the low likelihood of developing a full threshold episode
in that winter.
Randomization procedure
Participants are randomly allocated to one of the two
equal-probability, parallel, concurrent study treatments
on a continuous basis as they qualify for the study. The
schedule was designed by the project biostatistician/co-
investigator (PMV) and was reviewed by an independent
statistician prior to initiating the study. It was based on
permuted random-size blocks of four and six, stratified
by three variables: (1) sex, (2) major comorbid axis I
diagnosis with two levels (present/absent), and (3)
current antidepressant medication status with two levels
(on medication or not). The randomization schedule is
not available to anyone except the project statistician.
Only the project coordinator, who does not conduct any
assessments related to treatment outcome, is permitted
to randomize participants.
Treatments
Timing of the treatments
Participants enter the 6-week treatment phase on a con-
tinuous basis following randomization. The first week of
February is the last treatment start date each fall/winter
season of recruitment to ensure that all treatment is com-
pleted during the winter season and before spontaneous
springtime remission typically occurs.
Light therapy (LT)
Participants randomized to LT attend an instructional ses-
sion, standardized using a pre-generated script of points to
cover: the LT treatment rationale, demonstration of assem-
bly and positioning of the light box, prescription for daily
use (i.e., timing and duration), possible side effects, and ex-
planation of the daily LT self-monitoring diary and the side
effects questionnaire. These sessions are audiotaped to
assess treatment integrity. The PI conducts the sessions
because the PI and the project coordinator are the only un-
blinded personnel who work directly with participants, and
the PI is qualified to answer any questions that arise.
LT participants use the SunRay (SunBox Company,
Gaithersburg, MD), a standard LT unit (23 × 15½ × 3¼
inches) with an ultraviolet shield that emits 10,000 lux
of white fluorescent light to the retina when the user is
within 18 inches. Participants keep daily LT compliance
diaries to record the timing and duration of LT. For each
of the 6 treatment weeks, LT participants complete an
LT side effects questionnaire to assess the presence andseverity of any side effects attributed to LT (e.g., head-
ache, eyestrain, feeling “wired) and self-reported times
for onset of sleepiness, onset/offset of actual sleep, and
desired times for onset/offset of sleep over the previous
week. Although individuals typically respond within 4
weeks of initiating LT or not at all [7], our protocol is
maintained and monitored for a full 6 weeks to match the
duration of the CBTcondition. To circumvent ethical con-
cerns regarding discontinuation of a potentially beneficial
treatment during the winter when relapse is likely [1], par-
ticipants can choose to continue using the light box
through April and are asked to return it in May. However,
in an effort to reduce access to a suitable LT unit as a po-
tential confound, LT participants who wish to use LT in
the next fall/winter season are offered access to our light
boxes if they agree to consult a provider for side effects
management if needed. Continuing ongoing clinical man-
agement of LT under our supervision the next winter
would create a potentially important confound as we do
not offer to provide continued CBT or regular contact for
CBT-treated participants. The chosen strategy strikes a
balance between research design issues and ethical con-
cerns related to patient safety.
Each week while LT is being administered, the PI calls
the LT expert and co-investigator (TTP) to review weekly
SIGH-SAD scores and responses on the side effects ques-
tionnaire. Because morning light is a more potent anti-
depressant than evening light as shown by direct
comparisons [9,23] and because it has been suggested that
morning light manifests its effects via correcting a patho-
logical circadian phase-delay in SAD patients [24-26], LT
is initiated at 30 min in the morning, first thing upon
awakening, to be completed between the hours of 0600
and 0900 (i.e., in the phase advancing portion of the phase
response curve to light; [27]). After the first week, Dr.
Postolache recommends individually tailored, clinical ad-
justments to the duration of light use to maximize re-
sponse and reduce any reported side effects. After each
phone consult, the PI calls any LT participants with a
recommended change to their LT prescription to convey
the change. Increments in the duration of LT are initiated
in response to an insufficient response to light, defined as
a < 30% reduction in SIGH-SAD at the end of week 1, <
50% reduction in SIGH-SAD at the end of week 2, or not
fulfilling SIGH-SAD remission criteria at the end of week
3 and beyond. In these cases, if the side effect profile
permits, the duration of LT is increased in steps of
15 min/day up to a maximum of 2 h/day. Decrements in
LT are based on side effects and consist of decreases in LT
in 15-min increments/day. LT is temporarily halted for se-
vere side effects (e.g., severe migraines) and restarted the
following day with a reduced amount (50%), which is slowly
increased to tolerance. There are two concerns related to
circadian phase shifting induced by light: side effects of the
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dressing the phase shift. In a recent re-analysis of
Eastman et al.’s [28] data, evening light treatment for SAD
phase delayed and morning light treatment phase advanced
the temperature minimum (Tmin) by 1 h [29]. Early awak-
enings and/or late afternoon or early evening sleepiness
sometimes reported by patients could be the result of a cir-
cadian phase advance induced by the morning administra-
tion of LT. If this occurs, the duration of the morning LT is
reduced (if side effects present) and/or adjunct evening
light is added.
Cognitive-behavioral therapy (CBT)
The PI tailored traditional cognitive therapy for depres-
sion [12] to the SAD population in developing the CBT
for SAD protocol and its manual [30]. The treatment ra-
tionale addresses the role of environmental changes as
well as cognitions and behavior in the onset and main-
tenance of seasonal depressive symptoms. CBT for SAD
focuses on using traditional cognitive therapy elements
of behavioral activation and cognitive restructuring to
improve coping with winter. Behavioral activation is
presented as a means to experience enjoyment during
the fall/winter months by engaging in pleasurable activ-
ities. In addition to traditional cognitive restructuring of
depressogenic thoughts, this treatment also identifies
and challenges negative thoughts related to the winter
season, low light availability (i.e., short days, cloud
cover), and winter weather (e.g., cold temperatures,
snow). To cope with subsequent winter seasons, each
patient develops a personalized relapse-prevention plan,
involving early identification of negative anticipatory
thoughts about winter and of SAD-related behavior
changes that occur early in his/her episode and using
the skills learned to circumvent these prodromal signs of
a SAD episode to prevent relapse and recurrence. Al-
though cognitive therapy for depression is typically ad-
ministered for 20 standard length (50-min) sessions over
16 weeks, SAD necessitates an intensified version. With
winter lasting just 3 months, SAD patients may spontan-
eously remit with the arrival of spring if sessions were to
be conducted over 16 weeks. Therefore, the protocol in-
cludes 12 longer (1½-h) sessions at a higher frequency
(twice a week) over 6 weeks. Sessions are run in a small
closed-group format with 4–8 participants per CBT
group. Each group is led by a licensed PhD-level psych-
ologist with a clinical graduate student co-therapist. All
sessions are audiotaped to assess treatment adherence.
Therapist training/supervision
In addition to the PI therapist, two experienced (≥ 4 years
of practice beyond training at study outset) doctoral-
level community therapists facilitate the CBT groups,
supervised by the PI. Study therapists were recruitedwho had clinical experience with depression and experi-
ence in delivering CBT treatments, were able to commit
to the study, and were willing to learn the study treatment.
To train the therapists in the CBT for SAD protocol, the
PI conducted formal training sessions with the two thera-
pists together to review the session-by-session manual
content and to review and discuss audiotapes of past CBT
for SAD group sessions. During the first CBT group that
each study therapist led, the PI reviewed audiotapes of all
12 sessions as they occurred. Supervision during the first
CBT for SAD group consisted of 1.5-hour weekly meet-
ings between the PI and the group of therapists and
graduate student co-therapists involving a combination of
(1) group discussion of general issues in therapy, partici-
pant progress, and the treatment protocol and (2) individ-
ual time where the PI provided detailed feedback on the
prior two sessions to each therapist/co-therapist dyad.
After each therapist completed the first intensely super-
vised CBT group, the PI provided continued supervision
each year while CBT groups were ongoing by holding
weekly 1-hour meetings with the group of therapists and
co-therapists to discuss the sessions that occurred that
week. The PI continued to listen to a sample (20%) of all
CBT sessions conducted to monitor therapist adherence
to the protocol and to offer detailed feedback on a subset
of sessions. Study therapists are compensated for their
time in training and attending supervision at the going
rate for a clinical hour in VT and for their time in ad-
ministering CBT at the going per patient group therapy
rate in VT.
Treatment integrity
Because there were no pre-existing adherence/fidelity mea-
sures for CBT for SAD, the NIMH Collaborative Study Psy-
chotherapy Rating Scale (CSPRS; Steven D. Hollon, PhD,
personal communication, September, 2001), which mea-
sures the extent of specific therapist behaviors, was modi-
fied to measure adherence to our treatment protocols.
CSPRS scoring procedures have been manualized [31], and
adequate psychometric properties have been documented
[32,33]. Original CSPRS items assessing specific CBT inter-
vention components and nonspecific therapy aspects were
retained with added items to assess psychoeducational and
relapse-prevention components specific to our CBT ma-
nual. The language was modified to reflect group versus in-
dividual therapy. Items pertaining to clinical management
were rephrased to reflect LT (as opposed to imipramine). A
random sample (25%) of tapes is selected from each condi-
tion (CBT or LT) and session number and study therapist
(in the case of CBT). Two trained clinical graduate stu-
dents, blind to condition and session number, independ-
ently rate selected tapes. Inter-rater reliability and success
at discriminating between the content of the CBT and LT
conditions and between individual session numbers within
Rohan et al. Trials 2013, 14:82 Page 7 of 11
http://www.trialsjournal.com/content/14/1/82the CBT condition will be computed. Patient’s treatment
compliance is monitored by attendance and homework
completion (for CBT) and LT diaries (for LT).
Standardized information about ongoing and alternative
treatments after study treatment ends
As a step to increase the likelihood that treatment in the
interim is consistent with initial study treatment, stan-
dardized procedures are used for instructing participants
with regard to treatment alternatives at the end of study
treatment. When the treatment phase is complete in each
study year, all participants receive a standardized letter,
signed by the PI, encouraging them to keep up their study
treatment and to pursue new treatments only if needed.
Specifically, LT-treated participants receive a standard let-
ter encouraging them to re-initiate daily LT upon onset of
the first depressive symptom in the next fall/winter. The
letter reiterates that LT participants can borrow our light
boxes to use the next year as long as they have access to a
professional to whom they can turn in the event of side ef-
fects and also lists contact information for LT manufacturers
should they wish to purchase their own unit. CBT-treated
participants receive a standard letter encouraging them to
keep using the skills learned in the CBT for SAD treat-
ment on their own. Both letters include the same, stan-
dardized safety net in providing contact information for
local mental health centers and treatment providers
should they require more formal treatment. This approach
takes into account the ethical concern of not discouraging
participants from getting needed treatment between post-
treatment and the next winter follow-up while recognizing
that we cannot ethically proscribe treatment and are ac-
countable for directing them to resources.
Formal follow-up assessments
Three formal, in-person follow-up assessments occur sub-
sequent to study treatment completion: in the summer
(i.e., the subsequent August), the next winter (i.e., January
or February of the next wholly new winter season), and
the second winter (i.e., January or February of the second
wholly new winter season). All randomized participants
are invited to attend follow-ups.
Phone tracking of recurrences and retreatment
A blinded clinical graduate student telephones each par-
ticipant twice in the interim between summer follow-up
and the in-person next winter follow-up: once in October
and once in December. The purpose of these brief phone
contacts is to track any recurrences and any new treat-
ments initiated. To track recurrences, DSM-IV-TR criteria
for a major depressive episode on the SCID-CV are
assessed for the interval between the present and last
contact (i.e., formal assessment or phone call). To track
retreatment, the caller asks, “Have you started any newtreatments since (date of last contact) such as LT, talk
therapy, or medications?” If the participant answers af-
firmatively, he or she is queried for specific details.
Outcome measures
Structured Interview Guide for the Hamilton Rating Scale
for Depression—Seasonal Affective Disorder Version
(SIGH-SAD)
The SIGH-SAD [34] includes the 21-item Structured Inter-
view Guide for the Hamilton Rating Scale for Depression
(HAM-D) and a supplementary 8-item subscale to assess
atypical depressive symptoms associated with SAD. A
trained rater, blind to the treatment condition, administers
the SIGH-SAD at pre-treatment, treatment weeks 1–5,
post-treatment, summer follow-up, next winter follow-up,
and second winter follow-up. A second blinded rater subse-
quently rates audiotapes of the live SIGH-SADs to assess
inter-rater reliability.
The primary outcome, depression recurrence status in
the next winter, is defined according to the following
SIGH-SAD criteria [35]: total SIGH-SAD score ≥ 20 +
HAM-D score ≥ 10 + atypical score ≥ 5. The same criteria
are used to define SAD episode onset (i.e., study inclusion
criterion b) and depression recurrence status at follow-ups.
Continuous depression scores and remission status on the
SIGH-SAD represent secondary outcome measures. One
or both of the following SIGH-SAD criteria are used to
classify a full remission at post-treatment [36]: pre- to post-
treatment reduction in total SIGH-SAD score ≥ 50% +
HAM-D score ≤ 7 + atypical score < 7 OR HAM-D
score ≤ 2 + atypical score ≤ 10. These remission criteria are
also used to define remission status at the summer follow-
up and annual winter follow-ups, except that the respective
follow-up SIGH-SAD score, as opposed to the post-
treatment score, is contrasted to baseline status.
The Longitudinal Interval Follow-up Evaluation (LIFE)
The LIFE [36] is a semi-structured interview that assesses
the longitudinal course of psychiatric disorders, including
remissions and recurrences. This study uses the psycho-
pathology section of the LIFE, which provides weekly de-
pression status ratings on a continuous symptom scale
ranging from 1 (usual self; no residual depressive symp-
toms) to 6 (definite DSM-IV-TR Major Depressive Episode
criteria and extreme impairment), to assess depression in
the following three interim periods: between post-
treatment and the subsequent summer follow-up, between
summer follow-up and the next winter follow-up, and be-
tween the next winter follow-up and the second winter
follow-up. Any 2-week or longer period of depression rat-
ings in the range of 5 (the threshold for meeting DSM-IV-
TR Major Depressive Episode criteria) or 6 will be used as
a secondary outcome of depression recurrences that occur
between assessments. The LIFE was used in this way in a
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tive therapy or antidepressant medications to capture re-
lapse and recurrence [16,37]. A trained and blinded clinical
graduate student rater administers the LIFE live, and a sec-
ond blinded clinical graduate student rates an audiotape of
the LIFE to assess reliability for detecting recurrences in
these interim periods.Beck Depression Inventory—Second Edition (BDI-II)
The BDI-II [38] is a 21-item measure of depressive
symptom severity that constitutes a secondary outcome
measure, administered at pre- and post-treatment, sum-
mer, next winter, and the second winter. The BDI-II has
demonstrated good test-retest reliability and convergent
validity [38]. Consistent with the pilot trials [11,21,22],
BDI-II ≤ 8 is a secondary measure of remission status.
Protocol for training clinical raters and ensuring accuracy
of scores
To train SIGH-SAD raters, each year of recruitment, the PI
leads several sessions with the study team to discuss each
of the 29 SIGH-SAD items in detail and the nuances of
scoring them. Subsequently, each year, the raters practiced
rating at least three audiotapes of SIGH-SADs from past
studies and discussed their ratings in a group session lead
by the PI. Trainees were required to observe a veteran rater
perform a live SIGH-SAD in the study, record their ratings,
and discuss them with the interviewer after the session. To
become an independent rater, a trainee had to perform a
mock SIGH-SAD interview on the PI (role-playing a pa-
tient) with good flow and proficiency and obtain item rat-
ings that corresponded well to the PI’s judgments.
The following protocol was developed to increase the
accuracy of SIGH-SAD scores. The project statistician
identifies any SIGH-SAD administration with a 5-point or
greater discrepancy in total score (minus items H16 and
H17, which require a direct observation of the patient) be-
tween the original and second rater. In these cases
reaching the threshold for an unacceptable split between
raters, two additional blinded raters are selected from our
team to re-rate those particular interviews. The statisti-
cian then examines ratings from all four raters of each
tape to identify SIGH-SAD items where the original
rater disagreed with two or three of the other three
raters. Subsequently, the two new raters discuss those par-
ticular SIGH-SAD items and try to reach a consensus on
the most accurate score for them. If a consensus cannot
be reached, the PI is consulted about what was said on the
tape (keeping her blind to subject identity, and, therefore,
group assignment) to make a final decision about the most
accurate score for that item. Any corrected SIGH-SAD
scores will be used in the primary and secondary analyses.
However, inter-rater reliability statistics will still reflectagreement between the original (uncorrected) rater and
the second rater.
Data analysis plan
The primary analysis is an intent-to-treat (ITT) analysis
based on multiple imputation (MI) of missing next win-
ter SIGH-SAD scores [39-41]. Imputed scores will be
used to classify depression recurrence status for indivi-
duals who dropped out during the treatment phase, were
withdrawn from protocol, or were subsequently lost to
follow-up. Imputed values will be generated from multi-
variate normal models derived from subjects with next
winter follow-up data, using baseline and post-treatment
SIGH-SAD, HAM-D, and atypical scores, demographic
variables (e.g., gender, race, age), and other baseline pa-
tient characteristics (e.g., presence of a comorbid axis I
disorder, antidepressant medication status) as potential
predictors. Separate models will be developed for the
CBT and LT groups rather than including treatment
group in the model as a predictor, because in the pilot
study, baseline SIGH-SAD scores were negatively corre-
lated with next winter scores in CBT and were positively
correlated with next winter scores in LT. Outcomes for
subjects with missing next winter data will be predicted
from the models based on available data and a random
component reflecting the residual distribution for the
dependent variable. Ten data sets with different imputed
values will be generated, and a dichotomous variable in-
dicating recurrence status will be computed for each
subject based on SIGH-SAD criteria. The difference be-
tween the CBT and LT groups in the proportions of sub-
jects with a recurrence the next winter will be estimated
for each of the ten data sets and the estimates will be
combined using the inference methods for MI described
by Little and Rubin [42]. SAS PROC MI and PROC
MIANALYZE will be used to carry out the imputation
and analysis. Sensitivity analysis will be conducted to de-
termine the robustness of the results under alternative
MI models and imputation methods, including best and
worst case scenarios for each treatment.
The above analysis will be repeated using the following
alternate recurrence definitions as secondary outcomes: (1)
meeting SIGH-SAD recurrence criteria at the prospective
next winter follow-up OR depression recurrence defined as
any major depressive episode as assessed by the LIFE OR
fulfilling DSM-IV-TR major depression criteria in the in-
terim between summer and next winter as assessed by the
October and December tracking telephone calls, (2) a re-
currence on the next winter SIGH-SAD OR depression re-
currence status as assessed by considering any new
treatment reported in the interim between treatment end-
point and next winter follow-up (except for ongoing LT for
LT participants and using CBT skills on their own without
a therapist for CBT participants) as prima facie evidence of
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tive definition of recurrence that defines a recurrence as
fulfilling criteria (1) OR (2) above.
Secondary analyses will examine how potential modi-
fiers influence the effects of CBT and LT on the primary
outcome of next winter recurrence on the SIGH-SAD.
Potential modifiers will include: (1) demographic vari-
ables such as sex, age, and race (White vs. minority); (2)
baseline characteristics such as pre-treatment depression
scores, axis I comorbidity, and baseline antidepressant
medication status; and (3) complete or incomplete sum-
mer remission status in the interim, as ascertained by
the SIGH-SAD at the summer follow-up. This will be
done using logistic and linear regression analyses for di-
chotomous and continuous outcomes, respectively, and
including the modifiers as well as their interactions with
treatment in the models. Although the models are essen-
tially the same as those fitted to the complete data for the
purpose of imputation, for this analysis they will be fitted
to the imputed data sets, and the Rao-Blackwell estimates
of the effects of the modifiers will be obtained [43].
Discussion
The study design was selected to answer the primary
question: Do CBT and LT differ on depression recur-
rences during the subsequent winter season? The simple,
straightforward CBT vs. LT design will answer that ques-
tion and logically stems from pilot study findings. As a
time-limited treatment, if CBT is associated with better
outcomes than LT during the subsequent winter, CBT
may represent a more practical, effective approach to
long-term SAD management in clinical practice. The
unique methodological challenges faced here likely
generalize to designing intervention trials for other pre-
dictably recurrent and time-limited problems focused on
long-term outcomes. Justification for the chosen design,
consideration of alternative approaches, challenges faced
with this population, and areas for future study are
discussed below. Alternative designs would have re-
quired more patients, increased costs, and reduced
power to detect a difference in the primary outcome.Rationale for not designing to detect differences between
CBT and LT at treatment endpoint
The pilot study findings suggest that differences between
CBT and LT following 6 weeks of treatment are quite
small and that powering studies to detect these differences
would not represent cost-effective use of resources. For
example, 350 participants would be required in each treat-
ment arm (N = 700) for a 2-group Χ2 test with a two-
sided 0.05 significance level to achieve 80% power to
detect the 10% difference in proportions remitted on the
SIGH-SAD at post-treatment of 56% in LT vs. 46% in CBT(observed rates pooling across data from Rohan et al.,
2004, 2007). Moreover, the effect size associated with this
10% difference in remission is small, h = 0.20, and its
meaning is not clear in terms of cost-benefit. Similarly,
post-treatment differences between CBT and LT on con-
tinuous depression scores were consistently less than 2
points, a difference that is quite small and may not be clin-
ically meaningful. The central public health challenge with
regard to SAD is prevention of episode recurrence over
subsequent winter seasons. Therefore, the current trial fo-
cuses on detecting a significant and clinically meaningful
difference in the proportion of depressive episode recur-
rences between CBT and LT at the next winter follow-up
if this difference exists.Rationale for not designing to establish equivalence
between CBT and LT the next winter
The motivation for this trial is based on pilot data show-
ing that depression recurrence in the next winter season
may be substantially lower with CBT than with LT [11].
Therefore, it is more important to test whether depres-
sion recurrence in the subsequent winter is lower in
one treatment relative to the other than to test for
equivalence between CBT and LT. If CBT and LT are
“equivalent” (i.e., the true difference between the thera-
pies is functionally equivalent to zero, indicating the absence
of a difference between the treatments), it would require
280 subjects in each cell (N = 560) to test if recurrence
rates are equivalent within 10% (i.e., LT-CBT > −0.10). An
equivalence study of this size is not feasible or warranted
in light of the pilot data. Furthermore, a reduction of re-
currence would be the most, if not the only, compelling
reason for widespread adoption of CBT in clinical practice
because the vast majority of practitioners and researchers
who specialize in SAD have a chronobiological orientation
and enthusiasm for LT.Rationale for following all randomized participants vs.
only treatment responders
Although the more common approach in the nonseasonal
depression literature is to consider only the long-term out-
come of acute treatment responders rather than that for all
randomized participants, SAD patients are unique because,
by definition, they should spontaneously remit in the sum-
mer, which is prospectively assessed in this study. In
addition, focusing only on acute responders does not cap-
ture a potentially important clinical phenomenon whereby
it may be easier for SAD patients to use CBT in the preven-
tion of symptoms during the subsequent winter than in the
treatment of an acute SAD episode in the initial winter.
Therefore, we chose to follow all randomized participants.
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control group
The lack of other types of control groups here will not
allow determination of whether the treatments might be
equally ineffective, rather than comparably effective, in
the acute treatment of SAD. Instead, our primary aim
addresses the concern that the treatments might be
equally ineffective by testing for a meaningful difference
between treatments on depression recurrence in the
next winter. The addition of a wait-list control group is
not ethically justified in this study because participants
randomized to the wait-list would be asked to endure an
untreated major depressive episode in the initial winter
and also to endure the likely recurrence of their depres-
sion without treatment in the next winter season. In our
judgment, withholding treatment for two consecutive
fall/winter seasons would place these participants at sig-
nificant risk, and these safety concerns substantially out-
weigh the possible scientific benefit to be gleaned from
such a comparison.
Rationale for not including an attentional control group
If the efficacy of CBT for SAD becomes firmly established,
there are other valid questions that could be asked in fu-
ture studies that would require a different type of control
group. The present study does not address the question of
whether nonspecific factors such as group processes, so-
cial support, therapist attention, etc.—as opposed to the
cognitive and behavioral treatment components—are re-
sponsible for CBT’s observed treatment effects. Because
our CBT for SAD protocol is a relatively new treatment,
research designs that address its efficacy are more relevant
than designs addressing its mechanisms at this point. If
the pilot findings are replicated here and in future studies
at other sites, dismantling studies to isolate and identify
the active therapeutic components of our CBT will be in-
dicated. Such pursuits are premature to date.
Rationale for not including a combined CBT+LT treatment
In pilot studies [11,21-22], CBT+LT was associated with
the highest proportion of SIGH-SAD remissions at post-
treatment, but did not appear to show as much lasting
benefit as CBT alone over LT on next winter outcomes.
Moreover, a descriptive comparison of SIGH-SAD and
BDI-II remission rates at post-treatment to the next winter
remission rates suggests that only solo CBT treatment con-
tinued to improve from post-treatment status into the sub-
sequent winter season. In contrast, the remission rates
observed for solo LT and CBT+LT treatment appeared to
deteriorate somewhat from post-treatment to the next win-
ter. The reasons behind this apparent decay in CBT+LT’s
effects over the subsequent winter season are not known. It
is possible that participants benefited from combined treat-
ment in the initial winter because they fully engaged inboth protocols under the study team’s close monitoring
and supervision during the 6 weeks. During the subse-
quent winter season, however, CBT+LT participants had
to make a decision about what treatment(s) to continue
and how to balance the treatment components, which
might have contributed to perceived burden, treatment
overload, or attributing treatment effects to one treatment
over the other. Initial treatment with CBT alone may lead
to a more parsimonious course of action the next winter.
Although we might continue to explore the CBT+LT com-
bination and ways to augment its long-term effects in fu-
ture studies, the current project will test for a superiority
of one treatment over the other on depression recurrence
in the next winter, which is the next logical step in the de-
velopment and testing of CBT for SAD.Trial status
Recruitment for this trial has been ongoing since
September 2008.
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